INGAPORE — A young immuno-oncology company aims to pitch biomarker data for its lead drug candidate at the American Society of Clinical Oncology meeting in Chicago this summer, spreading the word about its ongoing Phase 3 trials.

Tessa Therapeutics could also send a message to fledgling Asian biotech hubs hoping to replicate the success of centers in other parts of the world.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.